EODData

MEMBERSHIP REGISTER LOG IN

FRA, 1C0: Celyad Oncology SA

10 Apr 2026
LAST:

0.2750

CHANGE:
 0.09		OPEN:
0.2750		HIGH:
0.2750		ASK:
0.0000		VOLUME:
0
CHG(%):
24.45		PREV:
0.3640		LOW:
0.2750		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Apr 260.27500.27500.27500.27500
09 Apr 260.27600.36400.27600.3640873
08 Apr 260.28400.28400.28400.28400
07 Apr 260.28000.28000.28000.28000
02 Apr 260.27400.27400.27400.27400
01 Apr 260.28000.28000.28000.28000
31 Mar 260.28000.28000.28000.28000
30 Mar 260.28000.28000.28000.28000
27 Mar 260.28100.28100.28100.28100
26 Mar 260.28000.28000.28000.28000

PROFILE

Name:Celyad Oncology SA
About:Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Address:Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
Website:https://celyad.com
ISIN:BE0974260896
LEI:549300ORR0M8XF56OI64

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.307.4%
MA10:0.294.7%
MA20:0.293.7%
MA50:0.280.5%
MA100:0.2226.4%
MA200:0.267.5%
STO9:1.11 
STO14:1.11 
RSI14:44.96
WPR14:-98.89 
MTM14:0.00
ROC14:0.00 
ATR:0.02 
Week High:0.3632.4%
Week Low:0.280.0%
Month High:0.3837.1%
Month Low:0.277.5%
Year High:0.5495.3%
Year Low:0.13114.0%
Volatility:168.50